Chinoin Laboratory has presented a new intravenous polymaltose iron treatment to address iron deficiency, a condition that causes symptoms such as fatigue, headaches, hair loss, brittle nails, and lack of concentration.
Dr. Francisco José Bernárdez Zapata, Head of the Gynecology and Obstetrics division at Hospital Español de México, highlights that this deficiency affects half of pregnant women in the world and one out of every 3 preschool-age children.
On the occasion of World Iron Deficiency Day, commemorated on November 26, it is emphasized that 50% of people suffering from anemia in the world have iron deficiency, according to the World Health Organization (WHO).
Chinoin seeks to improve the quality of life of patients with this new product, aimed at more than 25 million Mexicans.
Intravenous iron, such as the nanopharmaceutical Renegy (ferric carboxymaltose), has proven effective in promoting rapid increases in hemoglobin levels compared to oral treatments.
Renegy, administered intravenously in 15 minutes, stands out for its high safety and effectiveness profile, evidenced in the first 4 weeks of use.
Chinoin, with more than 90 years of existence, reaffirms its commitment to patient health, working together with healthcare professionals to improve the quality of life of the population.
With information from: MundodeHoy.
Receive all industry news in our weekly Newsletter Dialéctica Científica.